Review
Immunology
Wei Zhang, Chu Luo, Zun-Yi Zhang, Bi-Xiang Zhang, Xiao-Ping Chen
Summary: The combination of lenvatinib and pembrolizumab with GP chemotherapy achieved significant tumor reduction and decreased tumor marker levels in a patient with unresectable ICC. The patient underwent successful liver resection and has survived 15 months without recurrence or metastasis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zhengqing Lei, Weihu Ma, Anfeng Si, Yuhua Zhang, Facai Yang, Qiushi Yu, Haolan Tang, Qianru Xiao, Jiahua Zhou, Kui Wang, Yufu Tang, Tao Han, Guowen Yin, Jinhong Chen, Xiufeng Liu, Hua Zhao, Decai Yu, Tao Luo, Qing Wang, Maolin Yan, Xianhai Mao, Jing Li, Kai Wang, Jingdong Li, Yongyi Zeng, Dequan Ding, Tingsong Chen, Xiaofeng Wu, Yongxiang Xia, Kang Wang, Weixing Guo, Guangyu Zhu, Shan Gao, Norbert Hueser, Wan Y. Lau, Tianqiang Song, Shuqun Cheng, Feng Shen, Zhangjun Cheng
Summary: This study compared the efficacy of different anti-PD-1 combination therapies as the first-line treatment for uICC. The results showed that ICI-chemo and ICI-target therapies had better survival outcomes and fewer adverse events compared to chemotherapy. ICI-target-chemo had similar efficacy to ICI-chemo but resulted in more adverse events.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Immunology
Zhongyan Zhang, Xin Wang, Hehe Li, Huimin Sun, Jianhong Chen, Hongfeng Lin
Summary: We present a case of advanced intrahepatic cholangiocarcinoma (ICC) where radical surgery was not feasible due to tumor invasion. Six cycles of gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion. The patient subsequently underwent successful radical surgical resection, indicating that the GEMOX regimen combined with camrelizumab could be a potential conversion therapy strategy for advanced ICC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti-in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Aussara Panya
Summary: This study proposes a novel approach for treating cholangiocarcinoma by combining gemcitabine and PD-L1xCD3 BiTE, which enhances the cytotoxicity of T lymphocytes against CCA cells.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Md Masud Alam, Timothy Gower, Mengmeng Jiang, Joost J. Oppenheim, De Yang
Summary: TheraVac vaccine can cure multiple large tumors but not melanoma. Addition of cGAMP synergizes with TheraVac to activate DCs and enhance immune response. Treatment with cGAMP and TheraVac eradicates 60-80% of melanoma tumors and provides long-term protective immunity.
JOURNAL OF IMMUNOLOGY
(2023)
Review
Immunology
Huiling Wang, Yufei Xu, Fengli Zuo, Junzhi Liu, Jiqiao Yang
Summary: This article provides a systematic summary and analysis of immunotherapy-based combination therapies for esophageal cancer (EC), highlighting the clinical advantages and various treatment options, particularly the use of PD-1 monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Hongbo Chen, Kai Hou, Jing Yu, Le Wang, Xue Chen
Summary: Melanoma, an increasingly common form of skin cancer, poses challenges due to complications and drug resistance associated with traditional treatments. Combining nanoparticles with conventional methods offers a promising approach by efficiently targeting melanoma cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Hao Huang, Ling Peng, Bicheng Zhang, Brian G. Till, Yonghao Yang, Xiaojie Zhang, Lingdi Zhao, Xiaomin Fu, Tiepeng Li, Lu Han, Peng Qin, Lin Chen, Xiang Yan, Yang Liu, Wenkang Wang, Zhenlong Ye, Hongle Li, Quanli Gao, Zibing Wang
Summary: The study found that low-dose gemcitabine combined with PD-1 inhibitors showed efficacy in treating patients with advanced malignancies, with an objective response rate of 29.5% and a disease control rate of 62.3%. The most common adverse effects were hematological toxicity, primarily leukopenia or thrombocytopenia.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
David A. Bernal-Estevez, Mauren A. Ortiz Barbosa, Paola Ortiz-Montero, Claudia Cifuentes, Ramiro Sanchez, Carlos A. Parra-Lopez
Summary: This study investigates the safety and immunogenicity of autologous antigen-free DCs administered to breast cancer patients (BCPs) in combination with NAC-AC. The results suggest that the administration of DCs in combination with NAC-AC enhances the functional capacity of T cells in BCPs, potentially potentiating the adjuvant effect of ICD induced by NAC-AC on T cells and increasing the immunogenicity of tumors as cryptic vaccines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jing Yang, Xiaowen Chen, Xiaofang Li, Wenci Liu, Sihai Liao, Yuzhou Wang, Yufang Zuo
Summary: Primary osteosarcoma of the uterus is a rare type of cancer with limited information available. In this case report, the first clinical experience of using immunotherapy in combination with targeted therapy and chemotherapy for multiple metastatic primary osteosarcomas of the uterus is presented. After three cycles of treatment, the disease showed stability and partial remission, leading to improved quality of life and expected long-term survival for the patient.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang, Erlei Zhang
Summary: Cholangiocarcinoma (CCA) is a rare and aggressive type of cancer with increasing incidence in recent years. Surgery is the most effective treatment, but not suitable for all patients. Targeted therapy focusing on FGFR, IDH, and EGFR2, as well as immunotherapy with PD-1 inhibitors, CAR-T cells, and TILs, have shown promising results in CCA treatment. Combining targeted therapy, immunotherapy, and conventional chemotherapy can greatly improve the prognosis of advanced CCA patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Mei Peng, Di Xiao, Yizhi Bu, Jiahui Long, Xue Yang, Shuhe Lv, Xiaoping Yang
Summary: Bladder cancer therapy has seen two major breakthroughs with immune checkpoint inhibitors and FGFR-TKI erdafitinib, but challenges like low response rates and resistance remain. Combining immunotherapy with targeted drugs is a promising option to enhance response and combat resistance in managing bladder cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ryusei Matsuyama, Ryutaro Mori, Yohei Ota, Yuki Homma, Yasuhiro Yabusita, Seigo Hiratani, Takashi Murakami, Yu Sawada, Kentaro Miyake, Yasuhiro Shimizu, Takafumi Kumamoto, Itaru Endo
Summary: Gemcitabine/S-1 combination neoadjuvant chemotherapy shows promising efficacy and tolerability in the treatment of perihilar cholangiocarcinoma.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Xiao-hui Li, En-liang Zhou, Chong-yu Zhao, Bo-kang Cui, Xiao-yuan Dong, Hang Du, Xiao-jun Lin
Summary: Combining postoperative adjuvant chemotherapy with immunotherapy extends the relapse-free survival (RFS) and overall survival (OS) of patients with cholangiocarcinoma following radical resection.
Review
Oncology
Dimitrios Moris, Manisha Palta, Charles Kim, Peter J. Allen, Michael A. Morse, Michael E. Lidsky
Summary: Intrahepatic cholangiocarcinoma (ICC) is a common primary liver tumor, and the choice of treatment depends on the patient's condition. Doublet chemotherapy with gemcitabine and cisplatin has been the most effective first-line regimen, but triplet regimens and immunotherapy may also be effective. Combining systemic therapy with locoregional therapies and molecular targeted therapy have been developed to improve the treatment outcomes. Recent data showed that combining durvalumab with standard cytotoxic therapy improved survival in ICC patients.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Piriya Luangwattananun, Mutita Junking, Jatuporn Sujjitjoon, Yupanun Wutti-in, Naravat Poungvarin, Chanitra Thuwajit, Pa-thai Yenchitsomanus
Summary: The study demonstrates the specificity of fourth-generation FR alpha-CAR T cells in lysing breast cancer cells and their anti-tumor activity in spheroid cultures.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Yupanun Wutti-In, Jatuporn Sujjitjoon, Nunghathai Sawasdee, Aussara Panya, Katesara Kongkla, Pornpimon Yuti, Petlada Yongpitakwattana, Chutamas Thepmalee, Mutita Junking, Thaweesak Chieochansin, Naravat Poungvarin, Montarop Yamabhai, Pa-thai Yenchitsomanus
Summary: A new CAR T cell containing a fully human-derived anti-CD19 scFv was created, demonstrating superior anti-tumor activity against CD19(+) cancer cells with lower cytokine secretion levels.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Aussara Panya, Niphat Jirapongwattana, Primana Punnakitikashem, Thaweesak Chieochansin, Mutita Junking, Pa-thai Yenchitsomanus
Summary: This study evaluated the effectiveness of self differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) in activating T cells to kill multiple myeloma cells. T cells activated by SD-DC-BCMA showed dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high levels of IFN-gamma.
ANTICANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-Thai Yenchitsomanus
Summary: The study demonstrates that T cells secreting alpha CD133-alpha CD3 engager can be an alternative approach to treating CD133-positive CCA, and they exhibit high antitumor activity.
Article
Multidisciplinary Sciences
Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti-in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Aussara Panya
Summary: This study proposes a novel approach for treating cholangiocarcinoma by combining gemcitabine and PD-L1xCD3 BiTE, which enhances the cytotoxicity of T lymphocytes against CCA cells.
SCIENTIFIC REPORTS
(2022)
Article
Biotechnology & Applied Microbiology
Piriya Luangwattananun, Wannasiri Chiraphapphaiboon, Chanitra Thuwajit, Mutita Junking, Pa-Thai Yenchitsomanus
Summary: This study explores the potential of T lymphocytes activated by SmartDC-FR alpha as a treatment for FR alpha-expressing breast cancer. The results show that these activated T lymphocytes exhibit enhanced cytotoxicity against FR alpha-expressing breast cancer cells. This finding provides a new approach for utilizing ACT in the treatment of FR alpha-expressing breast cancer.
Article
Cell & Tissue Engineering
Kamonlapat Supimon, Thanich Sangsuwannukul, Jatuporn Sujjitjoon, Thaweesak Chieochansin, Mutita Junking, Pa-thai Yenchitsomanus
Summary: Researchers developed a novel CAR-T cell therapy targeting the overexpressed MUC1 protein on cholangiocarcinoma (CCA) cells. By introducing the PD-1-CD28 switch receptor into CAR-T cells, they were able to activate CD28 signaling and counteract the immune suppression caused by MUC1. The experimental results demonstrated that this new CAR-T cell showed enhanced anti-tumor activity, suggesting its potential for CCA treatment.
Article
Immunology
Pornpimon Yuti, Yupanun Wutti-in, Nunghathai Sawasdee, Katesara Kongkhla, Nattaporn Phanthaphol, Kornkan Choomee, Thaweesak Chieochansin, Aussara Panya, Mutita Junking, Pa-thai Yenchitsomanus, Jatuporn Sujjitjoon
Summary: Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells has shown promising results in the treatment of B-ALL and DLBCL. However, the efficacy in aggressive B cell lymphomas is limited due to poor T cell function caused by the interaction between PD-L1 on BCL cells and PD-1 receptor on T cells. To overcome this, researchers have generated anti-CD19-CAR5-T cells that secrete anti-PD-L1 scFv, which has shown improved antitumor efficiency against CD19+/PD-L1high tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Ployploen Phikulsod, Sanya Sukpanichnant, Chutima Kunacheewa, Thaweesak Chieochansin, Mutita Junking, Pa-Thai Yenchitsomanus
Summary: WT1 is a promising target antigen for cancer immunotherapy. This study confirms the high prevalence of WT1 expression in an Asian cohort of multiple myeloma patients, encouraging the development of immunotherapy targeting WT1, particularly in those with extramedullary plasmacytoma or relapsed disease.
PATHOLOGY & ONCOLOGY RESEARCH
(2023)
Article
Medicine, Research & Experimental
Pornpimon Yuti, Nunghathai Sawasdee, Krissada Natungnuy, Punchita Rujirachaivej, Piriya Luangwattananun, Jatuporn Sujjitjoon, Pathai Yenchitsomanus
Summary: Anti-BCMA-CAR5-T cells exhibit superior antitumor efficiency, proliferative capacity, and alleviated T-cell exhaustion against multiple myeloma cells.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Immunology
Jun Cui, Cheng Chen, Xiao Zhou, Wenju Shan, Yuhong Jian, Panpan Li, Yang Sun, Wei Yi
Summary: Bone marrow mesenchymal stem cells (BMSCs) are a promising therapy for sepsis, but metabolic syndromes threaten their effectiveness. This study investigated the potential of small extracellular vesicles from high-fat diet BMSCs in sepsis-induced liver-heart axis injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Binbin Zhu, Angyang Cao, Chunqu Chen, Weijian Zhou, Wenjun Luo, Yu Gui, Qinwen Wang, Zhipeng Xu, Jianhua Wang
Summary: GM6001 alleviates postoperative cognitive deficits and neuroinflammation, preserves blood-brain barrier integrity, and rescues aquaporin-4 mislocalization. MMP-9 inhibition plays a dual role in cognitive protection through direct anti-neuroinflammatory effects and regulation of aquaporin-4 membrane distribution.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Anika Sood, Valencia Fernandes, Kumari Preeti, Shruti Rajan, Dharmendra Kumar Khatri, Shashi Bala Singh
Summary: S1PR2 inhibitor improves cognitive function and skews microglia toward anti-inflammatory phenotype in type 2 diabetic mice, promising to be a potential therapy for neuroinflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Haochun Guo, Ran Yu, Haijun Zhang, Wanpeng Wang
Summary: Radiation therapy is an effective treatment for thoracic malignancies, but it can cause radiation-induced lung injury (RILI), including radiation pneumonitis (RP) and radiation pulmonary fibrosis (RPF). The damage to normal lung cells during radiation treatment leads to a pulmonary inflammatory response, resulting in RP and RPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Guanghui Wang, Haotian Zheng, Yunzhi Xiang, Yadong Wang, Kai Wang, Xiaoyang Ren, Jiajun Du
Summary: This study identified a T-cell synthetic driver-associated prognostic model that accurately predicted prognosis and effectiveness of immunotherapy in LUAD patients. It also highlighted the role of LDHA in promoting tumor cell proliferation, invasion, and resistance to treatment, as well as its involvement in immune escape within the tumor microenvironment. These findings provide a promising new therapeutic strategy for LUAD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Bowen Wei, Aihua Wang, Wei Liu, Qingyun Yue, Yihua Fan, Bin Xue, Siwei Wang
Summary: This study systematically analyzed the association between pSS and cuproptosis, established a predictive model based on 5 genes, explored the pathogenic mechanisms and novel therapeutic strategies for pSS, and identified EED, CBL, and NFU1 as potential targets for treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Nusrit Iqbal Andrabi, Aminur R. Sarkar, Syed Assim Haq, Diljeet Kumar, Dilpreet Kour, Diksha Saroch, Sanket Kumar Shukla, Ajay Kumar, Asha Bhagat, Asif Ali, Gurleen Kour, Zabeer Ahmed
Summary: Koenimbine and its novel semi-synthetic derivative 1G demonstrate significant anti-inflammatory effects by downregulating the nuclear factor kappa-B (NF-kappa B) signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Jing-Mei Lu, Xiang Xu, Fumie Aosai, Ming-Yue Zhang, Lian-Xun Piao
Summary: This study found that arctiin can improve allergic acute liver injury caused by T.g.HSP70 by inhibiting TLR4 signaling and reducing the production of inflammatory mediators.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Minxuan Xu, Fang Shi, Yongshen Gao, Shumei Han, Chensuo Huang, Qinsheng Hou, Xiaoweng Wen, Bengshi Wang, Zhenyu Zhu, Lei Zou, Mingxin Xiong, Wei Dong, Jun Tan
Summary: There is a growing body of research highlighting the involvement of metabolic imbalance and the inflammatory response in the advancement of colitis. This study recognizes arabinose as a significant protector of the intestinal mucosal barrier, reducing damage to the intestines. In addition, lower levels of arabinose in the bloodstream are associated with a higher severity of inflammatory bowel disease and colorectal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yueqing Han, Haoxin Song, Yanshan Li, Rongxin Li, Ling Chen, Bo Gao, Yijun Chen, Shuzhen Wang
Summary: The combination of tetracycline antibiotics, demeclocycline (D), chlortetracycline (C), and minocycline (M), showed therapeutic potential against liver fibrosis by inhibiting the activation of hepatic stellate cells and the MAPK signaling. This study suggests that tetracyclines may be repurposed for the treatment of liver fibrosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yu Li, Hailing Liu, Danwen Zhao, Danjie Zhang
Summary: Chronic stress can lead to lung injury, with the spleen playing a crucial role. This study found that the spleen contributes to chronic restraint stress-induced lung injury, and splenic CD11b+ cells may be an important factor in this process.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yingqian Mi, Mengyan Tang, Qiong Wu, Yinan Wang, Qihui Liu, Pei Zhu, Xiaoyang Xue, Yuntong Liu, Xinyu Chai, Yuyang Hou, Dongmei Yan
Summary: BCG therapy can induce macrophage polarization to the M1 type, and NMAAP1 plays a crucial role in this process by regulating glycolysis and HIF-1α expression. This promotes the antitumor effect of macrophages.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Xiaosheng Liu, Tingxia Lv, Xiuxia Li, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li
Summary: LLDT-8 exhibits notable efficacy in alleviating immune activation in both an in vivo animal model and in vitro human cell experiments, suggesting its potential as a drug for managing systemic immune activation associated with SIV/HIV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Honghong Yu, Qi Li, Huimin Zhu, Chang Liu, Weiwei Chen, Lingyun Sun
Summary: The activation of the inflammasome plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE), and mesenchymal stem cells (MSC) have been shown to alleviate SLE by suppressing inflammasome activation. This study found that the NLRP3 inflammasome was activated in macrophages from SLE patients and mice, and its activation correlated with disease activity. After MSC transplantation, the severity of SLE was reduced, and NLRP3 inflammasome activation was inhibited. These findings suggest that MSC suppress inflammasome activation and provide a potential therapeutic target for SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Wei Zhou, Dan Zeng, Shunan Liu, Yunxia Huang, Fenglin Lv, Weikang Zhou
Summary: This study found that inhibiting HDAC3 can protect the skin from atopic dermatitis by activating the Nrf2 transcription to upregulate Nrf2/HO-1 signaling pathway activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)